BRPI0507451A - method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulin - Google Patents
method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulinInfo
- Publication number
- BRPI0507451A BRPI0507451A BRPI0507451-7A BRPI0507451A BRPI0507451A BR PI0507451 A BRPI0507451 A BR PI0507451A BR PI0507451 A BRPI0507451 A BR PI0507451A BR PI0507451 A BRPI0507451 A BR PI0507451A
- Authority
- BR
- Brazil
- Prior art keywords
- metastases
- tumor growth
- development
- inhibit tumor
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
MéTODO E TERAPIA COMBINADA PARA INIBIR O CRESCIMENTO DE TUMOR E/OU PROGRESSãO METASTáTICA E/OU DESENVOLVIMENTO DE METáSTASES, E, USO DE UMA IMUNOGLOBULINA ANTI- ALFA4 INTEGRINA Composições, métodos e terapias combinadas para o tratamento de linfomas, leucemias, melanomas, câncer de próstata, e doença metastática são providos. Especificamente, as composições compreendendo imunoglobulinas anti-<244>4 integrina ou imunoglobulinas que se ligam a um ligando de <244>4 integrina (por exemplo MadCAM-1 e VCAM-1) são descritos para uso na inibição do crescimento de tumor e progressão e inibição de metástases. Uma imunoglobulina preferida para uso no tratamento de tumores e metástases é natalizumab. As composições e métodos usando estas imunoglobulinas podem ser usados sozinhos ou em combinação com outros reagentes e modalidades de tratamento de câncer.METHOD AND COMBINED THERAPY TO INHIBIT TUMOR GROWTH AND / OR METHASTATIC PROGRESS AND / OR METHODASE DEVELOPMENT, AND USE OF ANTI-ALPHA4 INTEGRINE IMMUNOGLOBULIN Combined compositions, methods and therapies for the treatment of lymphomas, leukemias, leukemias, cancer, prostate, and metastatic disease are provided. Specifically, compositions comprising anti-β4 integrin immunoglobulins or immunoglobulins that bind to a β4 integrin ligand (e.g. MadCAM-1 and VCAM-1) are described for use in inhibiting tumor growth and progression. and inhibition of metastases. A preferred immunoglobulin for use in the treatment of tumors and metastases is natalizumab. Compositions and methods using these immunoglobulins may be used alone or in combination with other cancer treatment reagents and modalities.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54194604P | 2004-02-06 | 2004-02-06 | |
PCT/US2005/002860 WO2005076843A2 (en) | 2004-02-06 | 2005-02-03 | Methods and compositions for treating tumors and metastatic disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507451A true BRPI0507451A (en) | 2007-07-10 |
Family
ID=34860234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507451-7A BRPI0507451A (en) | 2004-02-06 | 2005-02-03 | method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulin |
Country Status (19)
Country | Link |
---|---|
US (1) | US20050255118A1 (en) |
EP (2) | EP1718310A4 (en) |
JP (1) | JP4996261B2 (en) |
KR (1) | KR20070009581A (en) |
CN (1) | CN1946407B (en) |
AR (1) | AR047534A1 (en) |
AU (1) | AU2005213324B2 (en) |
BR (1) | BRPI0507451A (en) |
CA (1) | CA2555365A1 (en) |
EA (1) | EA009873B1 (en) |
IL (1) | IL177201A0 (en) |
MX (1) | MXPA06008746A (en) |
NO (1) | NO20063951L (en) |
NZ (1) | NZ584288A (en) |
PE (1) | PE20060009A1 (en) |
TW (1) | TWI375563B (en) |
UY (1) | UY28741A1 (en) |
WO (1) | WO2005076843A2 (en) |
ZA (1) | ZA200606557B (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2004000224A1 (en) | 2003-02-10 | 2005-01-21 | Elan Pharm Inc | STABLE PHARMACEUTICAL FORMULATION THAT INCLUDES AN IMMUNOGLOBULIN, A PHOSPHATE TAMPON, A POLYSORBATE AND SODIUM CHLORIDE, METHOD OF PREPARATION AND ITS USE. |
UY28716A1 (en) | 2004-01-09 | 2005-08-31 | Pfizer | ANTIBODIES AGAINST MADCAM |
WO2007007152A2 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
EP2109460B1 (en) | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
CA2708262A1 (en) * | 2007-12-07 | 2009-06-18 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating liquid tumors |
GB0800311D0 (en) * | 2008-01-09 | 2008-02-20 | Cytosystems Ltd | Apparatus and method for filtering biological material |
US20110110940A1 (en) * | 2008-04-15 | 2011-05-12 | Oxigene, Inc. | Methods for Enhancing the Efficacy of Vascular Disrupting Agents |
US20100158893A1 (en) * | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Systems and methods for obtaining immunoglobulin from blood |
AU2010236257A1 (en) * | 2009-04-17 | 2011-11-03 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
US20110158982A1 (en) * | 2009-10-05 | 2011-06-30 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM |
WO2012048275A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
SI3326645T1 (en) | 2010-10-25 | 2020-09-30 | Biogen Ma Inc. | Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels |
RU2665952C2 (en) | 2011-07-22 | 2018-09-05 | Пасилекс Фармасьютикалз Инк. | Synthetic lethality and the treatment of cancer |
US20160074337A1 (en) * | 2011-08-17 | 2016-03-17 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
WO2014018913A2 (en) * | 2012-07-27 | 2014-01-30 | University Of Connecticut | Santacruzamate a compositions and analogs and methods of use |
US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
RU2527154C1 (en) * | 2013-03-27 | 2014-08-27 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Method for increasing cisplatin bioavailability in experimentally induced sarcoma 45 |
RU2702428C2 (en) * | 2013-04-29 | 2019-10-08 | Огд2 Фарма | Use of o-acetylated gd2 ganglioside as target as novel therapeutic and diagnostic approach in malignant growths containing tumour stem cells |
EP3068867B1 (en) | 2013-11-16 | 2018-04-18 | Terumo BCT, Inc. | Expanding cells in a bioreactor |
KR102320190B1 (en) | 2014-01-24 | 2021-11-03 | 에이아이 테라퓨틱스, 인코포레이티드 | Apilimod Compositions and Methods for Using Same |
EP3122866B1 (en) | 2014-03-25 | 2019-11-20 | Terumo BCT, Inc. | Passive replacement of media |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
BR112017009000A2 (en) | 2014-11-07 | 2017-12-19 | Lam Therapeutics Inc | apilimod for use in the treatment of melanoma |
ES2741399T3 (en) | 2014-11-07 | 2020-02-10 | Ai Therapeutics Inc | Apilimod for use in the treatment of renal cancer |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
PL3325662T3 (en) | 2015-07-17 | 2024-02-26 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
CN117247899A (en) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | cell expansion |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
RU2650587C1 (en) * | 2017-04-26 | 2018-04-16 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Method of the melanoma b16 malignant growth in mice modification with chronic pain |
CR20200076A (en) | 2017-07-14 | 2020-06-10 | Pfizer | Antibodies to madcam |
AU2019337603A1 (en) * | 2018-09-13 | 2021-05-13 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
RU2762730C1 (en) * | 2021-03-30 | 2021-12-22 | Елена Рудольфовна Милаева | Means for inhibiting metastasis in the lungs |
RU2765955C1 (en) * | 2021-03-30 | 2022-02-07 | Елена Рудольфовна Милаева | Pulmonary metastasis inhibitor |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
CA2072249C (en) | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
NZ261259A (en) * | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
WO1996010585A1 (en) | 1994-09-30 | 1996-04-11 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US6235309B1 (en) * | 1997-02-28 | 2001-05-22 | The Regents Of The University Of California | Inhibition of cell-cell binding by lipid assemblies |
MY153569A (en) * | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
HU229038B1 (en) * | 1998-09-14 | 2013-07-29 | Regents Board Of | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
DE60043308D1 (en) | 1999-12-16 | 2009-12-24 | Biogen Idec Inc | METHOD FOR TREATING THE INJURY OF THE CENTRAL NERVOUS SYSTEM BY ISCHEMIA OR BY HEMORRHAGIA WITH ANTAGONISTS OF ALPHA4 INTEGRIN |
US20020076408A1 (en) * | 2000-12-08 | 2002-06-20 | Buchsbaum Donald J. | Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody |
JP2005506957A (en) * | 2001-06-11 | 2005-03-10 | トランジション・セラピューティックス・インコーポレーテッド | Combined treatment with vitamin B12 and interferon for the treatment of viral, proliferative and inflammatory diseases |
US7824680B2 (en) * | 2001-08-06 | 2010-11-02 | The Regents Of The University Of California | Methods for inhibiting angiogenesis |
US20040009169A1 (en) * | 2002-02-25 | 2004-01-15 | Julie Taylor | Administration of agents for the treatment of inflammation |
WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
EP1682179A4 (en) * | 2003-11-05 | 2008-09-03 | Palingen Inc | Enhanced b cell cytotoxicity of cdim binding antibody |
-
2005
- 2005-02-03 BR BRPI0507451-7A patent/BRPI0507451A/en not_active IP Right Cessation
- 2005-02-03 ZA ZA200606557A patent/ZA200606557B/en unknown
- 2005-02-03 US US11/049,365 patent/US20050255118A1/en not_active Abandoned
- 2005-02-03 NZ NZ584288A patent/NZ584288A/en not_active IP Right Cessation
- 2005-02-03 MX MXPA06008746A patent/MXPA06008746A/en active IP Right Grant
- 2005-02-03 WO PCT/US2005/002860 patent/WO2005076843A2/en active Application Filing
- 2005-02-03 KR KR1020067018079A patent/KR20070009581A/en active IP Right Grant
- 2005-02-03 EP EP05712339A patent/EP1718310A4/en not_active Withdrawn
- 2005-02-03 AU AU2005213324A patent/AU2005213324B2/en not_active Ceased
- 2005-02-03 CA CA002555365A patent/CA2555365A1/en not_active Abandoned
- 2005-02-03 EA EA200601433A patent/EA009873B1/en not_active IP Right Cessation
- 2005-02-03 JP JP2006552178A patent/JP4996261B2/en not_active Expired - Fee Related
- 2005-02-03 EP EP11005763A patent/EP2394652A3/en not_active Withdrawn
- 2005-02-03 CN CN2005800121486A patent/CN1946407B/en not_active Expired - Fee Related
- 2005-02-04 AR ARP050100431A patent/AR047534A1/en not_active Application Discontinuation
- 2005-02-04 UY UY28741A patent/UY28741A1/en unknown
- 2005-02-04 PE PE2005000129A patent/PE20060009A1/en not_active Application Discontinuation
- 2005-02-05 TW TW094103833A patent/TWI375563B/en not_active IP Right Cessation
-
2006
- 2006-08-01 IL IL177201A patent/IL177201A0/en unknown
- 2006-09-05 NO NO20063951A patent/NO20063951L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200536556A (en) | 2005-11-16 |
AR047534A1 (en) | 2006-01-25 |
WO2005076843A2 (en) | 2005-08-25 |
EA200601433A1 (en) | 2007-02-27 |
EP1718310A2 (en) | 2006-11-08 |
IL177201A0 (en) | 2006-12-10 |
UY28741A1 (en) | 2005-08-31 |
NZ584288A (en) | 2011-10-28 |
MXPA06008746A (en) | 2007-01-23 |
EP1718310A4 (en) | 2009-05-06 |
WO2005076843A3 (en) | 2006-01-26 |
JP4996261B2 (en) | 2012-08-08 |
EA009873B1 (en) | 2008-04-28 |
EP2394652A3 (en) | 2012-10-24 |
TWI375563B (en) | 2012-11-01 |
CN1946407A (en) | 2007-04-11 |
NO20063951L (en) | 2006-11-02 |
JP2007520557A (en) | 2007-07-26 |
CN1946407B (en) | 2011-10-05 |
ZA200606557B (en) | 2008-02-27 |
AU2005213324A1 (en) | 2005-08-25 |
CA2555365A1 (en) | 2005-08-25 |
EP2394652A2 (en) | 2011-12-14 |
PE20060009A1 (en) | 2006-02-11 |
AU2005213324B2 (en) | 2011-06-09 |
KR20070009581A (en) | 2007-01-18 |
US20050255118A1 (en) | 2005-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507451A (en) | method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulin | |
BR0210550A (en) | Method to enhance the effectiveness of cancer therapies | |
BRPI0612845A8 (en) | compound, pharmaceutical formulation, methods for treating cancer and for synthesizing a compound of formula | |
BRPI0509177A (en) | use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation | |
BRPI0515850A (en) | transport agents derived from cupredoxin and methods of using them | |
CL2012000913A1 (en) | Use of a pharmaceutical combination of specific compounds derived from 4-morpholinthieno [3,2-d] pyrimidine with 3,4-difluoro-2- (2-fluoro-4-iodophenylamino) phenyl) (3-hydroxy-3 - (( 2s) piperidin-2-yl) azetidin-1-yl) methanone to locally treat an advanced or metastatic solid tumor. | |
DE60334247D1 (en) | METHOD AND COMPOSITIONS FOR APOPTOSE INDUCTION IN CANCER CELLS | |
DE602005026508D1 (en) | MONOCYCLIC HETEROCYCLES AS KINASE-HEMMER | |
BR9805544C1 (en) | Use of a compound. | |
BR112022020769A2 (en) | CD73-INHIBITING COMPOUNDS OF 2,4-DIOXOPYRIMIDINE | |
DE602005026962D1 (en) | ARYLCARBOXAMIDES AND THEIR USE AS ANTITUMULAR AGENTS | |
Tsai et al. | Overexpression of histone H3 lysine 27 trimethylation is associated with aggressiveness and dedifferentiation of thyroid cancer | |
ATE473279T1 (en) | GLYCOPROTEIN ANTIGEN SIMA135 EXPRESSED IN METASTATIC HUMAN TUMOR CELLS | |
WO2003105773A3 (en) | Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets: | |
BRPI0411945A (en) | Antibodies and their uses | |
ATE339208T1 (en) | USE OF PROGESTERONE RECEPTOR INHIBITORS TO TREAT STEROID-RESISTANT BREAST CANCER | |
Ioannidis et al. | Eccrine porocarcinoma of the thumb in a patient with chronic exposure to benzene glue | |
Sakashita et al. | The incidence of late neck recurrence in N0 maxillary sinus squamous cell carcinomas after superselective intra-arterial chemoradiotherapy without prophylactic neck irradiation | |
NO20055650D0 (en) | Ruteinum (II) complexes for the treatment of tumors | |
UA88294C2 (en) | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation | |
ATE329597T1 (en) | THE USE OF A COMBINATION CONTAINING 4-PYRIDYLMETHYLPHTALAZINE FOR THE TREATMENT OF TUMORS | |
Zhao et al. | Combination of ibrutinib with ABT-199, a BCL-2 pathway inhibitor: effective therapeutic strategy in a novel mantle cell lymphoma cell line model | |
ATE461706T1 (en) | USE OF AN ANTI-PTHRP(34-53) ANTIBODY AS AN ANTAGONIST OF PTHRP FOR THE TREATMENT OF RENAL CELL CARCINOMA | |
Riaz | Expression Analysis of Sonic Hedgehog in Breast Cancer and its Relationship with Metastasis | |
Sledge Jr | Sunshine in New Orleans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |